23andMe Therapeutics Present Preliminary Phase 2 Safety And Efficacy Results For 23ME-00610, Targeting CD200R1, At The 2024 ASCO Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
23andMe Holding Co. (NASDAQ:ME) presented positive preliminary Phase 2 safety and efficacy data for its anti-CD200R1 antibody, 23ME-00610, at the 2024 ASCO Annual Meeting. The data showed clinical benefits, including a confirmed partial response, and acceptable safety and tolerability.
June 03, 2024 | 12:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
23andMe presented positive preliminary Phase 2 data for its anti-CD200R1 antibody, 23ME-00610, showing clinical benefits and acceptable safety at the 2024 ASCO Annual Meeting.
The positive preliminary Phase 2 data for 23ME-00610, including clinical benefits and acceptable safety, is likely to boost investor confidence and positively impact 23andMe's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100